Read by QxMD icon Read

Clinical Genitourinary Cancer

Ronald J Caras, Michael B Lustik, Sean Q Kern, Leah P McMann, Joseph R Sterbis
INTRODUCTION: Multiple studies have linked preoperative nutrition status to postoperative outcomes. This relationship has been little studied in urology. We used a standardized, national, risk-adjusted surgical database to evaluate 30-day outcomes of patients undergoing common urologic oncologic procedures as they related to preoperative albumin. METHODS: The American College of Surgeons National Surgical Quality Improvement Program is a risk-adjusted dataset analyzing preoperative risk factors, demographics, and 30-day outcomes...
September 23, 2016: Clinical Genitourinary Cancer
Thomas Martini, Christian Gilfrich, Roman Mayr, Maximilian Burger, Armin Pycha, Atiqullah Aziz, Michael Gierth, Christian G Stief, Stefan C Müller, Florian Wagenlehner, Jan Roigas, Oliver W Hakenberg, Florian Roghmann, Philipp Nuhn, Manfred Wirth, Vladimir Novotny, Boris Hadaschik, Marc-Oliver Grimm, Paul Schramek, Axel Haferkamp, Daniela Colleselli, Birgit Kloss, Edwin Herrmann, Margit Fisch, Matthias May, Christian Bolenz
INTRODUCTION: Guidelines recommend neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in patients with urothelial carcinoma of the bladder in clinical stages T2-T4a, cN0M0. We examined the frequency and current practice of NAC and sought to identify predictors for the use of NAC in a prospective contemporary cohort. MATERIALS AND METHODS: We analyzed prospective data from 679 patients in the PROMETRICS (PROspective MulticEnTer RadIcal Cystectomy Series 2011) database...
September 19, 2016: Clinical Genitourinary Cancer
Jeffrey J Tosoian, Michael A Gorin, Steven P Rowe, Darian Andreas, Zsolt Szabo, Kenneth J Pienta, Martin G Pomper, Tamara L Lotan, Ashley E Ross
No abstract text is available yet for this article.
September 19, 2016: Clinical Genitourinary Cancer
Allie E Steinberger, Patrick Cotogno, Elisa M Ledet, Brian Lewis, Oliver Sartor
No abstract text is available yet for this article.
September 17, 2016: Clinical Genitourinary Cancer
Thai H Ho, Rafael Nunez-Nateras, Yue-Xian Hou, Alan H Bryce, Donald W Northfelt, Amylou C Dueck, Bryan Wong, Melissa L Stanton, Richard W Joseph, Erik P Castle
BACKGROUND: Prostate tissue expresses 2 estrogen receptor (ER) isoforms, ER-α and ER-β, and estrogen-based therapies have shown activity in preclinical studies. Raloxifene, a selective ER modulator, has inhibited the growth of prostate cancer xenograft models and was tested in a phase II trial of castration-resistant prostate cancer (CRPC), with some patients achieving stable disease. However, no studies have examined the safety of the combination of bicalutamide plus raloxifene for CRPC...
September 8, 2016: Clinical Genitourinary Cancer
Norbert Marschner, Michael Staehler, Lothar Müller, Arnd Nusch, Johanna Harde, Michaela Koska, Martina Jänicke, Peter J Goebell
INTRODUCTION: Because "real-life" patients often do not meet the strict eligibility criteria of clinical trials, we assessed the trial eligibility of patients with advanced or metastatic renal cell carcinoma (mRCC) in routine practice and compared the survival of "trial-ineligible" and potentially "trial-eligible" patients. PATIENTS AND METHODS: The present prospective, multicenter German cohort study is recruiting patients from 110 oncology/urology outpatient centers and hospitals at initiation of systemic first-line treatment...
September 8, 2016: Clinical Genitourinary Cancer
Per Kongsted, Inge Marie Svane, Henriette Lindberg, Lisa Sengeløv
BACKGROUND: We investigated the impact of the number of docetaxel cycles administered in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line chemotherapy. PATIENTS AND METHODS: Charts from 421 consecutive patients who initiated standard treatment with docetaxel-based chemotherapy (75 mg/m(2) every 3 weeks) between 2007 and 2013 were reviewed. Patients who received < 6 cycles of docetaxel were excluded from the analysis...
September 8, 2016: Clinical Genitourinary Cancer
Andrea Necchi, Rosalba Miceli, Karima Oualla, Guru Sonpavde, Patrizia Giannatempo, Daniele Raggi, Nicola Nicolai, Roberto Boffi, Alessandra Busia, Luigi Mariani, Roberto Salvioni
BACKGROUND: Limited information is available about the effect of bleomycin administration on the development of pulmonary toxicity in metastatic germ cell tumors (GCT). PATIENTS AND METHODS: A literature search was conducted to identify randomized trials of first-line chemotherapy for GCT. We conducted univariate and multivariate analyses using random effects models to evaluate the predictive role of bleomycin administration in the development of all Grade and Grade 3 to 4 (G3-4) pulmonary toxicity...
September 8, 2016: Clinical Genitourinary Cancer
Giandomenico Roviello, Laura Zanotti, Angela Gobbi, Martina Dester, Daniele Generali, Chiara Pacifico, Maria Rosa Cappelletti, Alberto Bonetta
BACKGROUND: The aim of the present study was to evaluate the activity and tolerability of low-dose oral ethinylestradiol (EE) and luteinizing hormone-releasing hormone analogue with concomitant low-dose acetylsalicylic acid (ASA) as a thromboprophylactic agent for advanced castrate-resistant prostate cancer (CRPC). PATIENTS AND METHODS: The patients received an EE dose of 150 μg daily (50 μg 3 times daily) and an ASA dose of 100 mg once daily. The primary endpoint was the prostate-specific antigen response...
September 8, 2016: Clinical Genitourinary Cancer
Pavlos Msaouel, Miao Zhang, Shi-Ming Tu
No abstract text is available yet for this article.
September 7, 2016: Clinical Genitourinary Cancer
Hakmin Lee, Young Hyo Choi, Hyun Hwan Sung, Deok Hyun Han, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi
INTRODUCTION: We investigated the clinical prognostic value of preoperative De Ritis ratio (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]) on postsurgical survival outcomes in patients with upper tract urothelial cancer (UTUC). PATIENTS AND METHODS: We retrospectively analyzed the data of 623 patients who underwent radical nephrouretectomy for UTUC. Multivariate regression tests were performed to identify possible associations between adverse pathologic events and AST/ALT...
September 7, 2016: Clinical Genitourinary Cancer
Daniel M Moreira, Lauren E Howard, Katharine N Sourbeer, Hiruni S Amarasekara, Lydia C Chow, Dillon C Cockrell, Connor L Pratson, Brian T Hanyok, William J Aronson, Christopher J Kane, Martha K Terris, Christopher L Amling, Matthew R Cooperberg, Stephen J Freedland
OBJECTIVE: To identify the predictors of time from initial diagnosis of metastatic castration-resistance prostate cancer (mCRPC) to all-cause death within the Shared Equal Access Regional Cancer Hospital cohort. PATIENTS AND METHODS: We performed a retrospective analysis of 205 mCRPC men. Overall survival was estimated and plotted using the Kaplan-Meier method. The uni- and multivariable overall survival predictors were evaluated with the Cox proportional hazards model...
August 31, 2016: Clinical Genitourinary Cancer
Leilei Xia, Thomas J Guzzo
PURPOSE: The aim of this study was to determine the effect of preoperative anemia status and hemoglobin level on clinical outcomes in patients with bladder cancer undergoing radical cystectomy. MATERIALS AND METHODS: A systematic review of literature with meta-analyses of predefined outcomes based on a search of PubMed and EMBASE was performed. Hazard ratios (HRs) measuring the association between preoperative anemia/hemoglobin and all-cause mortality, cancer-specific mortality, and disease recurrence were calculated with random effects model...
August 29, 2016: Clinical Genitourinary Cancer
Valerio Vagnoni, Lorenzo Bianchi, Marco Borghesi, Cristian Vincenzo Pultrone, Hussam Dababneh, Francesco Chessa, Gaetano La Manna, Simona Rizzi, Angelo Porreca, Eugenio Brunocilla, Giuseppe Martorana, Riccardo Schiavina
PURPOSE: To assess survival and competing causes of mortality in prostate cancer (PCa) patients referred to radical prostatectomy through a combination of unfavorable characteristics. PATIENTS AND METHODS: We evaluated 615 PCa patients referred to radical prostatectomy and pelvic lymph node dissection at single tertiary-care center with at least one adverse feature (AF): preoperative prostate-specific antigen ≥ 20 ng/mL, pathologic Gleason score 8 to 10, and no organ-confined disease at final pathology (seminal vesicle involvement, positive surgical margins, and/or lymph node invasion)...
August 25, 2016: Clinical Genitourinary Cancer
Rana R McKay, Susanna Jacobus, Matthew Fiorillo, Elisa M Ledet, Patrick M Cotogna, Allie E Steinberger, Heather A Jacene, Oliver Sartor, Mary-Ellen Taplin
BACKGROUND: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of clinical trials have not been fully characterized. The primary objective in this study was to evaluate variables associated with completion of 5 to 6 radium-223 doses. PATIENTS AND METHODS: We conducted retrospective analyses of patients who received radium-223 (n = 135)...
August 20, 2016: Clinical Genitourinary Cancer
Zachary A Glaser, Matthew White, Elizabeth McKinley, Jeffrey S Glaser
No abstract text is available yet for this article.
August 20, 2016: Clinical Genitourinary Cancer
Avishay Sella, M Dror Michaelson, Ewa Matczak, Ronit Simantov, Xun Lin, Robert A Figlin
BACKGROUND: The Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) models categorize patients with 1 or 2 risk factors as intermediate prognosis (INTMP). This category encompasses 15 and 19 permutations of the MSKCC and IMDC risk factors, respectively. The purpose of the present retrospective analysis of data from INTMP patients in 6 clinical trials was to determine whether this heterogeneity influences the response to sunitinib...
August 18, 2016: Clinical Genitourinary Cancer
Moshe C Ornstein, Laura Wood, Paul Elson, Kimberly Allman, Jennifer Beach, Allison Martin, Timothy Gilligan, Jorge A Garcia, Brian I Rini
BACKGROUND: Given the variability in drug levels with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC), dose escalation at the occurrence of progressive disease (PD) might have antitumor effects. PATIENTS AND METHODS: The data from patients with mRCC who were treated at the Cleveland Clinic with TKIs and received a dose escalation after PD in accordance with Response Evaluation Criteria In Solid Tumors (RECIST), version 1...
August 18, 2016: Clinical Genitourinary Cancer
Randy F Sweis, Milica Medved, Shannon Towey, Gregory S Karczmar, Aytekin Oto, Russell Z Szmulewitz, Peter H O'Donnell, Paul Fishkin, Theodore Karrison, Walter M Stadler
INTRODUCTION/BACKGROUND: Traditional imaging assessment criteria might not correlate well with clinical benefit from vascular endothelial growth factor pathway-directed therapy in metastatic renal cancer. Preclinical data suggest tumor growth is preceded by a rise in K(trans) level, a parameter derived from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) that reflects vascular permeability. We thus hypothesized that K(trans) might be a predictive biomarker for pazopanib...
August 17, 2016: Clinical Genitourinary Cancer
Nathan Osbun, Brian Winters, Sarah K Holt, George R Schade, Daniel W Lin, Jonathan L Wright
INTRODUCTION: Sertoli and Leydig cell tumors (SCT and LCT) are uncommon testis neoplasms. Data regarding patient demographics and outcomes are limited to small series. We further characterized these tumors using a large cancer database. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was queried from 2004 to 2012. International Classification of Diseases for Oncology (ICD-O) codes identified SCT and LCT. Common germ cell tumors (GCT) provided a reference group...
August 12, 2016: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"